Research Overview
Peptides for Best Peptides for Hormone Optimization
A research overview of peptides studied for growth hormone axis modulation, ranked by evidence level and mechanistic specificity.
GH secretagogue peptides fall into two mechanistic categories: GHRH analogs that stimulate pituitary GH release directly, and ghrelin mimetics that amplify GH pulses through a complementary receptor pathway. Understanding this distinction is essential for evaluating the research on individual compounds and combination protocols.
What This Page Covers
This page reviews the peptides with the most documented research relevant to GH axis modulation and hormone optimization. Evidence levels range from formerly FDA-approved compounds with clinical outcomes data to research peptides with pharmacokinetic data only. No compound reviewed here is currently FDA-approved for hormone optimization in healthy adults.
Two Pathways to GH Axis Stimulation
Mechanism 01
GHRH Pathway
CJC-1295 and sermorelin act on GHRH receptors on pituitary somatotrophs. This is the same pathway as endogenous GHRH, stimulating GH gene transcription and preserving pulsatile release.
Mechanism 02
Ghrelin Pathway
Ipamorelin and MK-677 act on GHS-R1a ghrelin receptors, a separate pathway that amplifies GH pulses. Combining a GHRH analog with a ghrelin mimetic produces synergistic GH release through dual pathway stimulation.
Mechanism 03
DAC vs No DAC
CJC-1295 with DAC uses albumin binding to extend half-life to 6-8 days, enabling weekly dosing. CJC-1295 without DAC (Mod GRF 1-29) has a short half-life requiring multiple daily doses but produces a more physiologically pulsatile GH release pattern.
Peptides Commonly Discussed for Best Peptides for Hormone Optimization
Ordered by evidence level.
CJC-1295
Human TrialsGHRH receptor agonism; DAC albumin binding extends half-life to 6-8 days
The most pharmacokinetically characterized research GHRH analog. Phase II data confirms 2-10 fold GH elevation sustained for 6-8 days with DAC formulation. No published outcomes data for body composition or performance.
Sermorelin
Human TrialsGHRH receptor agonism; endogenous GHRH N-terminal fragment
The first 29 amino acids of endogenous GHRH. Formerly FDA-approved for pediatric GH deficiency with human outcomes data. The most clinically validated GHRH analog available.
Ipamorelin
Animal StudiesGHS-R1a agonism; highly selective with no off-target hormone elevation
The most selective ghrelin mimetic. Stimulates GH without elevating cortisol, ACTH, or prolactin. Frequently paired with CJC-1295 for dual-pathway GH stimulation.
MK-677
Animal StudiesGHS-R1a agonism; oral bioavailability via non-peptide structure
The only orally bioavailable GH secretagogue in this category. Phase II data shows sustained GH and IGF-1 elevation. Less selective than ipamorelin, elevates cortisol and prolactin.
Quick Comparison
| Peptide | Primary Mechanism | Evidence | Research Context |
|---|---|---|---|
| CJC-1295 | GHRH receptor agonism; DAC albumin binding extends half-life to 6-8 days | Human Trials | Phase II human PK data; not FDA-approved; development program inactive |
| Sermorelin | GHRH receptor agonism; endogenous GHRH N-terminal fragment | Human Trials | Formerly FDA-approved; withdrawn commercially; human outcomes data available in approved populations |
| Ipamorelin | GHS-R1a agonism; highly selective with no off-target hormone elevation | Animal Studies | Limited human PK data; strong preclinical selectivity evidence; not FDA-approved |
| MK-677 | GHS-R1a agonism; oral bioavailability via non-peptide structure | Animal Studies | Phase II human data; not FDA-approved; less selective than peptide GHRPs |
What the Research Suggests
Best Evidence for Best Peptides for Hormone Optimization
GH secretagogue peptides reliably elevate GH and IGF-1 in human pharmacokinetic studies. The critical unresolved question is whether this hormone elevation translates to meaningful clinical outcomes in healthy adults. The evidence gap between hormone biomarker data and clinical outcomes data is the defining limitation of this entire category.
Strongest Individual Compound
Sermorelin for clinical validation in GH-deficient populations. CJC-1295 for pharmacokinetic characterization among current research peptides. Ipamorelin for selectivity profile. GH stimulation without off-target hormone elevation.
What This Category Cannot Do
No current compound in this category is FDA-approved for hormone optimization in healthy adults. Hormone elevation data does not equal clinical outcomes data. Long-term safety of sustained IGF-1 elevation carries epidemiological cancer risk concerns that have not been resolved in this compound class.
PSI Reading of the Evidence Gap
Hormone optimization research covers two distinct types of evidence. Pharmacokinetic data confirms that GH secretagogues reliably elevate GH and IGF-1 markers in human studies. Clinical outcomes data connecting those elevated markers to health improvements in healthy adults is at an earlier stage of development. Sermorelin and tesamorelin have the most established clinical track records through FDA approval histories. CJC-1295 and Ipamorelin have documented human pharmacokinetic profiles. Both types of evidence are relevant and represent different stages of clinical development.
How to Choose
Research-informed guidance for peptides studied in the context of best peptides for hormone optimization. Not a recommendation.
Most selective ghrelin mimetic with no cortisol or prolactin elevation
Ipamorelin (Animal Studies)
Regulatory Status
4 available through compounding.
Important Limitations
Formerly Approved
- Sermorelin, formerly FDA-approved for pediatric GH deficiency; now research use only
Research Peptides
- CJC-1295 (Phase II human data only
- Ipamorelin) limited human data
- MK-677, Phase II human data; oral; less selective
Key Safety Considerations
Sustained GH and IGF-1 elevation carries theoretical long-term cancer risk concerns. None of these compounds are FDA-approved for use in healthy adults. Clinical supervision is strongly recommended.
No compound in this category is currently FDA-approved for hormone optimization in healthy adults.
Pharmacokinetic data confirming GH elevation is not equivalent to clinical outcomes data.
Long-term safety of sustained IGF-1 elevation is not established.
CJC-1295 development program is inactive. Reasons for non-progression are undisclosed.
MK-677 is less selective than peptide GHRPs. It also elevates cortisol and prolactin.
Combination protocols (CJC-1295 + ipamorelin) lack controlled outcomes data despite widespread use.
Explore More
Related Hubs
Who This May Apply To
Individuals researching which peptides have the strongest evidence for GH axis modulation.
Healthcare providers comparing GHRH analogs and ghrelin mimetics for GH secretagogue protocols.
Researchers evaluating the distinction between DAC and no-DAC CJC-1295 formulations.
Individuals comparing the selectivity profiles of ipamorelin versus MK-677.